Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer
The introduction of the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib to the adjuvant setting marks a significant advancement in the treatment of hormone-receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer (HR+, HER2− EBC). Despi...
Kaydedildi:
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publishing
2025-03-01
|
| Seri Bilgileri: | Therapeutic Advances in Medical Oncology |
| Online Erişim: | https://doi.org/10.1177/17588359251326710 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|